ClinicalTrials.gg
CompletedNCT00990990Updated Aug 28, 2013

Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

A Phase 1 interventional study of PNU-100480 and Placebo in Tuberculosis, sponsored by Sequella, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-28.

Sponsored by Sequella, Inc. · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing linezolid in Tuberculosis — 3 open to participants now, 4 under way, 1 of them phase 3. Linezolid · Tuberculosis.

Enrollment
13th of 15
59 · median 154
Started
2009
the only one that year
Phase 1
Only one
of the 15
Registered
3rd of 15
by date
Lead sponsor
1 of 15
Sequella, Inc.

Among the 15 studies testing linezolid in Tuberculosis, this one is the 13th largest by enrollment, is the only one that started in 2009, is the only one in phase 1, and was the 3rd registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

3 of the 15 studies testing linezolid in Tuberculosis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About linezolid

Linezolid: first FDA approval 2000 (ZYVOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing linezolid in Tuberculosis, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of multiple doses of PNU-100480 given for 14 or 28 days. Killing activity against the bacterium that causes tuberculosis (TB) will also be measured. The effect of adding an additional tuberculosis (TB) agent (given for 2 days) in addition to PNU-100480 will be evaluated. Linezolid open label to determine activity in whole blood assay (WBA).

Read the detailed description

Evaluate safety, tolerability, pharmacokinetics and whole blood activity (WBA) of PNU-100480 given for 14 or 28 days; evaluate WBA of PNU with pyrazinamide; evaluate WBA of linezolid

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Safety tolerability pharmacokinetics (PK) pharmacodynamics whole blood activity (WBA) PNU-100480 linezolid pyrazinamide multiple dose
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers willing and able to be confined to the Clinical Research Unit and comply with study schedule.
  • Women of non- only.

Exclusion criteria

Exclusion Criteria:

  • History of to, or intolerance of, linezolid.
  • Antibiotic treatment within 14 days prior to dosing, or any previous antibiotic use at the discretion of the investigator.
  • Previous history of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Cohort 2

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Cohort 3

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Cohort 4

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Cohort 5

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Cohort 6 (optional)

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Linezolid Cohort

    Drug: Linezolid

Interventions

  • 100 mg BID for 14 days

  • DrugPlacebo

    to match 100 mg BID for 14 days

  • 300 mg BID for 14 days

  • DrugPlacebo

    to match 300 mg BID for 14 days

  • 600 mg BID for 14 days

  • DrugPlacebo

    to match 600 mg BID for 14 days

  • 1200 mg QD for 14 days

  • DrugPlacebo

    to match 1200 mg QD for 14 days

  • 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28

  • DrugPlacebo

    placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28

  • PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28

  • DrugPlacebo

    placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28

  • 300 mg QD for 4 days (open label)

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of ascending oral doses of PNU-100480 administered as extemporaneously prepared suspension (EPS) over 14 and 28 days in healthy adult volunteers.

    Time frame: Monitor adverse events daily; safety eval pre-dose, specified times , discharge, follow-up/as needed

Secondary outcomes

  1. To characterize the single dose and steady state pharmacokinetics of ascending oral doses of PNU-100480 administered over 14 and 28 days in healthy adult volunteers with regard to the parent drug and its metabolites.

    Time frame: Full and sparse PK sampling from Day 1 through final day of dosing

  2. To characterize the bactericidal activity in blood of orally administered PNU-100480 against intracellular M. tuberculosis in relation to blood concentrations ofPNU-100480 and its metabolites.

    Time frame: Full and sparse sampling from Day 1 through final day of dosing

  3. To characterize the effect of once a day administration of pyrazinamide for 2 days on the pharmacokinetics and bactericidal activity in blood of orally administered PNU-100480 against intracellular M. tuberculosis (Cohorts 5 and 6, Days 27-28 only).

    Time frame: Days 27-28 as applicable

  4. To characterize pharmacokinetics and bactericidal activity in blood of orally administered linezolid against intracellular M. tuberculosis following 4 days of QD dosing.

    Time frame: As applicable up to Day 4

07

Study locations

1 site
  • Pfizer Investigational Site
    New Haven, Connecticut 06511, United States
08

References and documents

Publications

  • Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis. 2010 Sep 1;202(5):745-51. doi: 10.1086/655471. PubMed 20629533 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2009
First posted
Oct 7, 2009
Start
Oct 2009
Primary completionActual
May 2010
CompletionActual
May 2010
Last update
Aug 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00990990
Lead sponsor
Sequella, Inc.
Responsible party
Sponsor
First posted
Oct 7, 2009
Start date
Oct 2009
Primary completion
May 2010
Completion
May 2010
Last update
Aug 28, 2013

Study contacts

Lisa Beth Ferstenberg, M.D.
study director · Sequella, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PNU-100480 · Linezolid

Start the discussion